PuraPharm Corporation Limited (1498.HK)
HKD 0.5
(-1.0%)
HKD 0.5
(-1.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -106.08 Million HKD | 11.76% |
| 2022 | -120.21 Million HKD | 1.36% |
| 2021 | -121.87 Million HKD | -484.35% |
| 2020 | 31.71 Million HKD | 113.95% |
| 2019 | -227.25 Million HKD | -1192.27% |
| 2018 | 20.8 Million HKD | 1001.43% |
| 2017 | 1.88 Million HKD | -94.13% |
| 2016 | 32.16 Million HKD | 13.02% |
| 2015 | 28.45 Million HKD | -17.42% |
| 2014 | 34.46 Million HKD | 31.22% |
| 2013 | 26.26 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -18.68 Million HKD | 72.68% |
| 2023 Q2 | -37.67 Million HKD | 53.09% |
| 2023 FY | -106.08 Million HKD | 11.76% |
| 2023 Q4 | -68.4 Million HKD | -81.57% |
| 2022 FY | -120.21 Million HKD | 1.36% |
| 2022 Q4 | -80.31 Million HKD | -101.27% |
| 2022 Q2 | -39.9 Million HKD | 70.19% |
| 2021 Q2 | 11.97 Million HKD | -40.94% |
| 2021 FY | -121.87 Million HKD | -484.35% |
| 2021 Q4 | -133.85 Million HKD | -1217.85% |
| 2020 Q2 | 11.43 Million HKD | 106.28% |
| 2020 FY | 31.71 Million HKD | 113.95% |
| 2020 Q4 | 20.27 Million HKD | 77.26% |
| 2019 FY | -227.25 Million HKD | -1192.27% |
| 2019 Q2 | -45.18 Million HKD | -705.79% |
| 2019 Q4 | -182.07 Million HKD | -303.01% |
| 2018 FY | 20.8 Million HKD | 1001.43% |
| 2018 Q4 | 7.45 Million HKD | -44.13% |
| 2018 Q2 | 13.34 Million HKD | 284.14% |
| 2017 Q2 | 9.13 Million HKD | -61.73% |
| 2017 Q4 | -7.24 Million HKD | -179.33% |
| 2017 FY | 1.88 Million HKD | -94.13% |
| 2016 FY | 32.16 Million HKD | 13.02% |
| 2016 Q2 | 8.28 Million HKD | -77.02% |
| 2016 Q4 | 23.87 Million HKD | 188.2% |
| 2015 Q2 | -7.59 Million HKD | -127.14% |
| 2015 FY | 28.45 Million HKD | -17.42% |
| 2015 Q4 | 36.05 Million HKD | 574.64% |
| 2014 Q4 | 27.98 Million HKD | 332.16% |
| 2014 FY | 34.46 Million HKD | 31.22% |
| 2014 Q2 | 6.47 Million HKD | -24.93% |
| 2013 FY | 26.26 Million HKD | 0.0% |
| 2013 Q4 | 8.62 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 200.992% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 105.643% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 34.899% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | -590.811% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | -101.273% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 735.292% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 138.539% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | -267.788% |
| SSY Group Limited | 1.31 Billion HKD | 108.045% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 181.311% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 139.735% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 102.752% |